Drugs / HP568
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06757335 | Jan 2025 → Jan 2026 overdue | breast cancer | Hinova Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP568 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06757335 ↗ |
| Route | Oral | “Daily oral dosages of HP568 for 28 days” NCT06757335 ↗ |